Closed-loop Insulin Delivery: Update on the State of the Field and Emerging Technologies

Overview

Journal Expert Rev Med Devices

Specialties Pharmacology
Radiology

Date 2022 Nov 4

PMID 36331211

Authors

Julia Ware

Roman Hovorka

Affiliations

Soon will be listed here.

Abstract

Introduction: Over the last five years, closed-loop insulin delivery systems have transitioned from research-only to real-life use. A number of systems have been commercialized and are increasingly used in clinical practice. Given the rapidity of new developments in the field, understanding the capabilities and key similarities and differences of current systems can be challenging. This review aims to provide an update on the state of the field of closed-loop insulin delivery systems, including emerging technologies.

Areas Covered: We summarize key clinical safety and efficacy evidence of commercial and emerging insulin-only hybrid closed-loop systems for type 1 diabetes. A literature search was conducted and clinical trials using closed-loop systems during free-living conditions were identified to report on safety and efficacy data. We comment on emerging technologies and adjuncts for closed-loop systems, as well as non-technological priorities in closed-loop insulin delivery.

Expert Opinion: Commercial hybrid closed-loop insulin delivery systems are efficacious, consistently improving glycemic control when compared to standard therapy. Challenges remain in widespread adoption due to clinical inertia and the lack of resources to embrace technological developments by health care professionals.

Citing Articles

Effects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.

Kogai T, Sato J, Yasuda H, Ayame T, Ozaki A, Takagi E J Diabetes Investig. 2024; 16(2):326-333.

PMID: 39513544 PMC: 11786187. DOI: 10.1111/jdi.14350.

Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions.

Rimon M, Hasan M, Hassan M, Cesmeci S Pharmaceutics. 2024; 16(7).

PMID: 39065641 PMC: 11279469. DOI: 10.3390/pharmaceutics16070944.

Efficacy of automated insulin delivery in pregnant women with type 1 diabetes: a meta-analysis and trial sequential analysis of randomized controlled trials.

Teixeira T, Godoi A, Romeiro P, Novaes J, Faria F, Pereira S Acta Diabetol. 2024; 61(7):831-840.

PMID: 38700546 DOI: 10.1007/s00592-024-02284-3.

Effects of hybrid closed-loop system on glycemic control and psychological aspects in persons with type 1 diabetes treated with sensor-augmented pump: A prospective single-center observational study.

Akiyama T, Yamakawa T, Orime K, Ichikawa M, Harada M, Netsu T J Diabetes Investig. 2023; 15(2):219-226.

PMID: 37934090 PMC: 10804894. DOI: 10.1111/jdi.14103.

Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials.

Godoi A, Marques I, Padrao E, Mahesh A, Hespanhol L, Riceto Loyola Junior J Diabetol Metab Syndr. 2023; 15(1):190.

PMID: 37759290 PMC: 10537468. DOI: 10.1186/s13098-023-01144-4.

References

Thabit H, Prabhu J, Mubita W, Fullwood C, Azmi S, Urwin A . Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. Diabetes Care. 2020; 43(10):2537-2543. DOI: 10.2337/dc20-0736. View

Pease A, Zomer E, Liew D, Earnest A, Soldatos G, Ademi Z . Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2020; 22(11):812-821. DOI: 10.1089/dia.2020.0064. View

Hovorka R, Allen J, Elleri D, Chassin L, Harris J, Xing D . Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010; 375(9716):743-51. DOI: 10.1016/S0140-6736(09)61998-X. View

Andreozzi F, Candido R, Corrao S, Fornengo R, Giancaterini A, Ponzani P . Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetol Metab Syndr. 2020; 12:52. PMC: 7301473. DOI: 10.1186/s13098-020-00559-7. View

Schoelwer M, Sherr J, Weyman K, Tichy E, VanName M, Brei M . Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care. 2022; 45(8):1907-1910. PMC: 9346983. DOI: 10.2337/dc21-2359. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Mair C, Wulaningsih W, Jeyam A, McGurnaghan S, Blackbourn L, Kennon B . Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016. Diabetologia. 2019; 62(8):1375-1384. PMC: 6647722. DOI: 10.1007/s00125-019-4900-7. View

Tanenbaum M, Iturralde E, Hanes S, Suttiratana S, Ambrosino J, Ly T . Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users. J Health Psychol. 2017; 25(4):429-438. PMC: 7162558. DOI: 10.1177/1359105317718615. View

Boughton C, Hovorka R . New closed-loop insulin systems. Diabetologia. 2021; 64(5):1007-1015. PMC: 8012332. DOI: 10.1007/s00125-021-05391-w. View

10.

Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, Godot C . Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health. 2022; 4(3):e158-e168. DOI: 10.1016/S2589-7500(21)00271-5. View

11.

Tauschmann M, Hermann J, Freiberg C, Papsch M, Thon A, Heidtmann B . Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry. Diabetes Care. 2020; 43(3):e40-e42. DOI: 10.2337/dc19-1358. View

12.

Addala A, Auzanneau M, Miller K, Maier W, Foster N, Kapellen T . A Decade of Disparities in Diabetes Technology Use and HbA in Pediatric Type 1 Diabetes: A Transatlantic Comparison. Diabetes Care. 2020; 44(1):133-140. PMC: 8162452. DOI: 10.2337/dc20-0257. View

13.

Russell S, Hillard M, Balliro C, Magyar K, Selagamsetty R, Sinha M . Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016; 4(3):233-243. PMC: 4799495. DOI: 10.1016/S2213-8587(15)00489-1. View

14.

Brown S, Kovatchev B, Raghinaru D, Lum J, Buckingham B, Kudva Y . Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019; 381(18):1707-1717. PMC: 7076915. DOI: 10.1056/NEJMoa1907863. View

15.

Iturralde E, Tanenbaum M, Hanes S, Suttiratana S, Ambrosino J, Ly T . Expectations and Attitudes of Individuals With Type 1 Diabetes After Using a Hybrid Closed Loop System. Diabetes Educ. 2017; 43(2):223-232. PMC: 7162535. DOI: 10.1177/0145721717697244. View

16.

Lum J, Bailey R, Barnes-Lomen V, Naranjo D, Hood K, Lal R . A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2020; 23(5):367-375. PMC: 8080906. DOI: 10.1089/dia.2020.0535. View

17.

Kimbell B, Rankin D, Ashcroft N, Varghese L, Allen J, Boughton C . What Training, Support, and Resourcing Do Health Professionals Need to Support People Using a Closed-Loop System? A Qualitative Interview Study with Health Professionals Involved in the Closed Loop from Onset in Type 1 Diabetes (CLOuD) Trial. Diabetes Technol Ther. 2020; 22(6):468-475. PMC: 7262645. DOI: 10.1089/dia.2019.0466. View

18.

Lanzinger S, Best F, Bergmann T, Laimer M, Lipovsky B, Danne T . Dynamics of Hemoglobin A1c, Body Mass Index, and Rates of Severe Hypoglycemia in 4434 Adults with Type 1 or Type 2 Diabetes After Initiation of Continuous Glucose Monitoring. Diabetes Technol Ther. 2022; 24(10):763-769. DOI: 10.1089/dia.2022.0063. View

19.

Breton M, Kovatchev B . One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021; 23(9):601-608. PMC: 8501470. DOI: 10.1089/dia.2021.0097. View

20.

Kamble S, Weinfurt K, Schulman K, Reed S . Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial. Med Decis Making. 2012; 33(2):215-24. DOI: 10.1177/0272989X12464824. View